Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
7 Countries Where You Can Buy a Home for Under $100,000 - 2Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- 3Figure out how to Consolidate All encompassing Practices with a Degree in Brain research
- 4Chicago reports first rabies-positive dog in 61 years. What we know.
- 5Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Want to make America healthy again? Stop fueling climate change
- Meet the astronauts about to make history on flight around the moon
- Surveys of 6 Hot Savvy Beds
- The Developing Nearby Food Development and Its Advantages
- What to expect from the planets in 2026 — key dates and sky events
- Top 10 Moving Style Architects of the Year
- Hezbollah field commander killed in IDF strikes in Beirut
- Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- ByHeart baby formula from all lots may be contaminated with botulism bacteria, tests show
